Business

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @

articleCormedix Inc.March 2, 20261/company/cormedix-inc/news/cormedix-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-5-2026
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

About this update from Cormedix Inc.

[{"type":"image","alt":"CorMedix, Inc.","displaySize":"","headline":null,"caption":"CorMedix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":151,"url":"https://media.zenfs.com/en/globenewswire.com/04a828931a8de73e15b3cb965f763d93"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C_G0R9JUmQlTsNvTh1B0Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04a828931a8de73e15b3cb965f763d93","width":300,"height":151}},"lazy":false},{"type":"text","content":"BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.","length":478,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"max-width:25%;min-width:25%;vertical-align:top;","val":[{"type":"text","content":"Thursday, March 5th @ 8:30am ET","length":31,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:25%;width:25%;min-width:25%;vertical-align:top;","val":[{"type":"text","content":"Domestic:","length":9,"tagName":"p","attribs":{}}]},{"style":"max-width:75%;width:75%;min-width:75%;vertical-align:top;","val":[{"type":"text","content":"1-844-676-2922","length":14,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"International:","length":14,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"1-412-634-6840","length":14,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Webcast:","length":8,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Webcast Link","length":12,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]}],"length":144},{"type":"text","content":"About Cor...

More updates from Cormedix Inc.

biopharmaceutical companyCorMedixcentral venous catheterbloodstream infections